Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
The deal puts more support behind targeting folate receptor α, a long troubled target, with antibody-drug conjugates.
But this week three transactions did squeak through.
And Royalty Pharma has paid a king’s ransom.
The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
And consolidation in the diagnostics space is only just beginning.